See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
KANZHUN LIMITED Sponsored ADR (BZ) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KANZHUN LIMITED Sponsored ADR (BZ) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for April 18th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 18th:
Verrica Pharmaceuticals Inc. (VRCA - Free Report) : This clinical-stage dermatology therapeutics company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.4% over the last 60 days.
Verrica Pharmaceuticals Inc. Price and Consensus
Verrica Pharmaceuticals Inc. price-consensus-chart | Verrica Pharmaceuticals Inc. Quote
Verrica’s shares gained 48.3% over the last three months compared with the S&P 500’s advance of 6.6%. The company possesses a Momentum Score of A.
Verrica Pharmaceuticals Inc. Price
Verrica Pharmaceuticals Inc. price | Verrica Pharmaceuticals Inc. Quote
Kanzhun Limited (BZ - Free Report) : This online recruitment platform from China has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.3% over the last 60 days.
KANZHUN LIMITED Sponsored ADR Price and Consensus
KANZHUN LIMITED Sponsored ADR price-consensus-chart | KANZHUN LIMITED Sponsored ADR Quote
Kanzhun’s shares gained 18.5% over the last six months compared with the S&P 500’s advance of 11.8%. The company possesses a Momentum Score of A.
KANZHUN LIMITED Sponsored ADR Price
KANZHUN LIMITED Sponsored ADR price | KANZHUN LIMITED Sponsored ADR Quote
Annovis Bio, Inc. (ANVS - Free Report) : This clinical-stage drug platform company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.8% over the last 60 days.
Annovis Bio, Inc. Price and Consensus
Annovis Bio, Inc. price-consensus-chart | Annovis Bio, Inc. Quote
Annovis’ shares gained 24.9% over the last three months compared with the S&P 500’s advance of 6.6%. The company possesses a Momentum Score of B.
Annovis Bio, Inc. Price
Annovis Bio, Inc. price | Annovis Bio, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.